| Description | (R)-Lansoprazole (T 168390) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) |
| In vitro | Dexlansoprazole在口服lansoprazole后构成血液中超过80%的化合物循环，与S-对映体相比，展现更低的清除率以及5倍以上的系统暴露度。Dexlansoprazole MR是dexlansoprazole的改良缓释制剂，采用独特的双延迟释放（DDR）技术。该技术分两个独立阶段释放化合物，从而抑制原始PPI失活的H+,K+-ATPase后新激活的质子泵。与lansoprazole相比，Dexlansoprazole MR维持化合物在血等级中上述阈值的时间更长。[1] Dexlansoprazole通过直接抑制胃壁细胞中的H+K+-ATPase质子泵，选择性地抑制胃酸分泌，最终阻断酸性物质生产的最后一个步骤。[2] |
| Synonyms | Dexlansoprazole, 右旋兰索拉唑, T 168390, TAK 390, R-(+)-Lansoprazole |
| molecular weight | 369.36 |
| Molecular formula | C16H14F3N3O2S |
| CAS | 138530-94-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (148.91 mM) Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Metz DC, et al. Aliment Pharmacol Ther, 2009, 29(9), 928-937. 2. Emerson CR, et al. Clin Ther, 2010, 32(9), 1578-1596. 3. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297. |
| Citations | 1. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches. RSC Advances. 2018 Jan 8(10): 5286-5297. |